Precision AQ

Hannah DeresiewiczExecutive Vice President, Managing Director

Hannah Deresiewicz is an Executive Vice President and Managing Director of Investor Relations & External Communications at Precision AQ, where she leads a team that supports biotech and pharmaceutical clients through critical inflection points, including IPOs, M&A transactions, and major clinical and commercial milestones. As a seasoned communications strategist with deep expertise in investor relations, public relations, and corporate communications for life sciences companies, Hannah’s career spans over a decade of advising companies at the forefront of innovation, helping them navigate the complexities of public markets and strategic growth. Hannah has played a key role in supporting dozens of transactions, including IPOs, PIPEs, follow-on offerings, and high-profile acquisitions. Her insights into capital markets and stakeholder engagement make her a trusted partner to executive teams and boards preparing for transformative events.

Let's talk

Insights from Hannah Deresiewicz

Market Outlook Q4 2025: Antibody-Drug Conjugates (ADCs) Image

Commercialization & Access | White Paper Market Outlook Q4 2025: Antibody-Drug Conjugates (ADCs)

Wall Street Perspective on Radiopharmaceuticals Image

Commercialization & Access | White Paper Wall Street Perspective on Radiopharmaceuticals